Embecta Corp. (EMBC) stock
EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 15/3080% below fair value
$6.15−0.10 (-1.60%)
Close on Nov 17, 2026Market cap $348.46MP/E 4.2Yield 9.76%
Embecta operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Embecta's operating income for the twelve months ending Jun 30, 2026 was $223.50M, up 5.5% year over year. For fiscal 2025 it was $242.10M, up 45.1% from the year before. The highest annual figure on record is $492.00M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $242.10M | +45.1% |
| FY2024 | Sep 30, 2024 | $166.80M | -24.7% |
| FY2023 | Sep 30, 2023 | $221.50M | -28.5% |
| FY2022 | Sep 30, 2022 | $309.60M | -37.1% |
| FY2021 | Sep 30, 2021 | $492.00M | +1.1% |
| FY2020 | Sep 30, 2020 | $486.50M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $48.70M | -48.2% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $35.00M | -44.4% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $83.30M | +190.2% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $56.50M | +115.6% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $94.00M | +68.2% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $62.90M | +60.5% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $28.70M | -36.9% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $26.20M | +1.6% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $55.90M | +9.0% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $39.20M | -29.5% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $45.50M | -48.8% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $25.80M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $51.30M | -47.2% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $55.60M | -43.8% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $88.80M | -23.8% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$3.00M | -102.6% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $97.10M | -21.9% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $98.90M | -21.8% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $116.60M | -6.0% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $117.20M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $124.30M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $126.40M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $124.10M | – |
See a number that looks wrong?